VJOncology is committed to improving our service to you

ESMO 2020 | GINECO TAPAZ clinical trial update

VJOncology is committed to improving our service to you

Florence Joly

Florence Joly, MD, PhD, Centre François Baclesse, Caen, France, discusses the GINECO randomized Phase II TAPAZ (NCT02383251) study, comparing the use of paclitaxel with or without pazopanib in ovarian cancer patients with relapse during bevacizumab maintenance therapy. Primary endpoint was progression-free survival (PFS), results did not show an increase in PFS in favour of the combination treatment, with Prof. Joly concluding that the combination treatment is not really feasible. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter